The Duke University Health System and School of Medicine have launched a precision medicine study called OneDukeGen that will integrate comprehensive genomic data and clinical information to foster a deeper understanding of hereditary disease susceptibilities.
Led by Principal Investigator Svati Shah, M.D., M.H.S., a cardiologist and associate dean of genomics, the study aims to recruit more than 100,000 consented Duke patients to participate in the research.
The purpose of the OneDukeGen Genomic Sequencing Study and Biorepository (OneDukeGen) is to collect biological samples, and use the samples to analyze DNA, and other material (like RNA) for use in research related to a variety of diseases and conditions.
The study, in partnership with vendor nference, is committed to ensuring representation of diverse populations as well as equitable return of genetic sequencing results in research. The design of OneDukeGen is rooted in inclusivity and was formed by incorporating a diverse range of perspectives gained from engaging community groups, according to the health system.
Duke researchers and clinicians will work in tandem to integrate research findings into patient care. By bridging the gap between scientific discovery and clinical practice, we are poised to usher in a new era of healthcare delivery.
In an online interview with Mary Klotman, M.D., dean of the Duke University School of Medicine, Shah said Duke is building on what other universities have begun in terms of bringing the best in genetics and other technologies to their programs. “This will allow us to take our scientific discoveries and translate them to patient care in a shorter period of time, which is really a major focus of the program,” she added. “Another way that we're different is we're really taking a science-forward approach in asking the questions: what are the key science questions that remain unanswered, and how can we use genetics and precision medicine to answer those questions?”
